Allergy Thera. Share News (AGY)
AGY Share
AGY Share
AGY Share
AGY Share
AGY
AGY Share
AGY Level 2
AGY Live
AGY Broker
AGY Directors
AGY Financial
AGY
AGY Short
AGY
Last checked at -
Mon, 26th Oct 2020 14:17
Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Screens first patient in exploratory field study of Grass MATA MPL immunotherapy on patient who suffer from allergic symptoms when exposed to grass.
Current stock price: 13.29 pence
Year-to-date change: up 30%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
(Alliance News) - Stock prices in London at midday continued to be weighed down by the worrying surge in Covid-19 cases as China swiftly re-opens from three years of strict lockdown measures.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.
Read more(Alliance News) - Stock prices in London opened lower on Thursday amid risk-off sentiment across Europe, as concerns grew about rising Covid cases in China.
Read moreAlliance News) - Allergy Therapeutics PLC on Thursday said it shares will be suspended next week, due to delays in completing the audit of its annual results.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.
Read more(Alliance News) - Allergy Therapeutics PLC on Thursday saw shares drop despite the start of its peanut allergy testing trial, after it confirmed that cost control remains a preoccupation for management following a pause in production earlier in the year.
Read more(Alliance News) - Allergy Therapeutics PLC on Monday said it appointed Martin Hopcroft as interim chief financial officer, as Nick Wykeman will step down at the end of November.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
Read moreAllergy Therapeutics PLC - West Sussex-based commercial biotechnology company - Says it will resume production at Freeman facility in Worthing, UK on November 14. This follows a short-term voluntary pause as it reviewed its operating processes. Says the pause was planned, to help improve "robustness" of quality systems and build capacity. It was then accelerated when the firm realised capacity could not cope with commercial demand. "The pause in manufacturing occurred during a period of peak production prior to the start of the pollen season in the spring," it says. Consequently, it estimates revenue will be around 13% to 18% lower than market expectations of around GBP80 million, for the year to June 30.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more
(Sharecast News) - Biotechnology company Allergy Therapeutics has "proactively paused" production at the Freeman facility, part of its Worthing manufacturing site, to accelerate ongoing site improvements, it announced on Tuesday.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
Read more(Alliance News) - Allergy Therapeutics PLC shares dropped on Tuesday following production at the Freeman facility, part of its Worthing, UK manufacturing site, being paused.
Read more(Alliance News) - Allergy Therapeutics PLC shares dropped on Tuesday following production at the Freeman facility, part of its Worthing, UK manufacturing site, being paused.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more
Last checked at